Endocannabinoid Binding to the Cannabinoid Receptors: What is Known and What Remains Unknown

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2010 Feb 20

PMID 20166921

Citations 80

Authors

Patricia H Reggio

Affiliations

Soon will be listed here.

Abstract

The cannabinoid CB1 and CB2 receptors are Class A G protein-coupled receptors (GPCRs). While many Class A GPCRs have endogenous ligands that are hydrophilic cations (e.g., the serotonin and dopamine receptors), the cannabinoid receptors have neutral, highly lipophilic ligands derived from the fatty acid, arachidonic acid. The most well-studied of these are N-arachidonoylethanolamine (anandamide, AEA) and sn-2-arachidonoylglycerol (2-AG). This review focuses on the experimental and computational studies that have been used to probe the nature of endocannabinoid interaction with the cannabinoid receptors. These studies include mutation, SAR and NMR studies, as well as, QSAR, docking and molecular dynamics simulations. Gaps in our knowledge are identified. The review begins more generally, however, by discussing the entire endocannabinoid system, of which the cannabinoid receptors are part. For in order to understand endocannabinoid action, one needs an appreciation for the environments for which these ligands have been designed and the conformational changes these ligands must undergo in order to act on the cannabinoid receptors.

Citing Articles

Dynamic Mechanism for Subtype Selectivity of Endocannabinoids.

Dutta S, Zhao L, Shukla D bioRxiv. 2024; .

PMID: 39554065 PMC: 11565827. DOI: 10.1101/2024.10.25.620304.

"Elucidating the immunomodulatory role of endocannabinoids in intervertebral disc degeneration".

Vasudevan G, Ramachandran K, Tangavel C, Nayagam S, Gopalakrishnan C, Muthurajan R Eur Spine J. 2024; 34(1):308-315.

PMID: 39542877 DOI: 10.1007/s00586-024-08550-w.

Interplay between cannabinoids and the neuroimmune system in migraine.

Zorrilla E, Della Pietra A, Russo A J Headache Pain. 2024; 25(1):178.

PMID: 39407099 PMC: 11481476. DOI: 10.1186/s10194-024-01883-3.

Endocannabinoid concentrations in major depression: effects of childhood maltreatment and relation to hippocampal volume.

Mazurka R, Harkness K, Hassel S, Stensson N, Nogovitsyn N, Poppenk J Transl Psychiatry. 2024; 14(1):431.

PMID: 39394160 PMC: 11470058. DOI: 10.1038/s41398-024-03151-z.

Towards a New Dynamic Interaction Model of Adolescent CUD Manifestation, Prevention, and Treatment: A Narrative Review.

Oosten W, Vos E, Los L, Nelwan M, Pieters T Psychoactives. 2024; 2(4):294-316.

PMID: 39280928 PMC: 7616443. DOI: 10.3390/psychoactives2040019.

References

Ryan W, Banner W, Wiley J, Martin B, Razdan R . Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J Med Chem. 1997; 40(22):3617-25. DOI: 10.1021/jm970212f. View

Franklin A, Stella N . Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors. Eur J Pharmacol. 2003; 474(2-3):195-8. DOI: 10.1016/s0014-2999(03)02074-0. View

Jagerovic N, Fernandez-Fernandez C, Goya P . CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr Top Med Chem. 2008; 8(3):205-30. DOI: 10.2174/156802608783498050. View

Lange J, Coolen H, van Stuivenberg H, Dijksman J, Herremans A, Ronken E . Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J Med Chem. 2004; 47(3):627-43. DOI: 10.1021/jm031019q. View

Padgett L, Howlett A, Shim J . Binding mode prediction of conformationally restricted anandamide analogs within the CB1 receptor. J Mol Signal. 2008; 3:5. PMC: 2289822. DOI: 10.1186/1750-2187-3-5. View

Suhara Y, Oka S, Kittaka A, Takayama H, Waku K, Sugiura T . Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorg Med Chem. 2006; 15(2):854-67. DOI: 10.1016/j.bmc.2006.10.049. View

Hillard C, Manna S, Greenberg M, DiCamelli R, Ross R, Stevenson L . Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J Pharmacol Exp Ther. 1999; 289(3):1427-33. View

Ghanouni P, Steenhuis J, Farrens D, Kobilka B . Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A. 2001; 98(11):5997-6002. PMC: 33412. DOI: 10.1073/pnas.101126198. View

Idris A, van t Hof R, Greig I, Ridge S, Baker D, Ross R . Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med. 2005; 11(7):774-9. PMC: 1430341. DOI: 10.1038/nm1255. View

10.

Hanus L, Fride E, Breuer A, Vogel Z, Shalev D, Kustanovich I . 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci U S A. 2001; 98(7):3662-5. PMC: 31108. DOI: 10.1073/pnas.061029898. View

11.

Berglund B, FLEMING P, Rice K, Shim J, Welsh W, Howlett A . Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation. Drug Des Discov. 2000; 16(4):281-94. View

12.

Bezuglov V, Bobrov M, Gretskaya N, Gonchar A, Zinchenko G, Melck D . Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg Med Chem Lett. 2001; 11(4):447-9. DOI: 10.1016/s0960-894x(00)00689-2. View

13.

Porter A, Sauer J, Knierman M, Becker G, Berna M, Bao J . Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 2002; 301(3):1020-4. DOI: 10.1124/jpet.301.3.1020. View

14.

Sawzdargo M, Nguyen T, Lee D, Lynch K, Cheng R, Heng H . Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res. 1999; 64(2):193-8. DOI: 10.1016/s0169-328x(98)00277-0. View

15.

Rice W, Shannon J, Burton F, Fiedeldey D . Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone. Eur J Pharmacol. 1997; 327(2-3):227-32. DOI: 10.1016/s0014-2999(97)89665-3. View

16.

Shen C, Xiao J, Armstrong H, Hagmann W, Fong T . F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Eur J Pharmacol. 2006; 531(1-3):41-6. DOI: 10.1016/j.ejphar.2005.12.026. View

17.

Hanus L, Gopher A, Almog S, Mechoulam R . Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem. 1993; 36(20):3032-4. DOI: 10.1021/jm00072a026. View

18.

Salo O, Raitio K, Savinainen J, Nevalainen T, Lahtela-Kakkonen M, Laitinen J . Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J Med Chem. 2005; 48(23):7166-71. DOI: 10.1021/jm050565b. View

19.

Felder C, Joyce K, Briley E, Glass M, Mackie K, Fahey K . LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther. 1998; 284(1):291-7. View

20.

Shim J, Howlett A . WIN55212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction. J Chem Inf Model. 2006; 46(3):1286-300. DOI: 10.1021/ci0504824. View